Details Basic Details Approval Date Tuesday, April 23, 2019 Health Outcome(s) adverse pregnancy and fetal outcomes, lymphoma, malignancy Regulatory Link(s) (2) ARIA Memo FDA Approval Package Link(s) Sentinel Drug Study: Skyrizi (Risankizumab) & Lymphoma